Quality of life considerations in gynecologic cancer

被引:102
作者
Penson, Richard T.
Wenzel, Lari B.
Vergote, Ignace
Cella, David
机构
[1] Univ Calif Irvine, Ctr Hlth Policy Res, Coll Med, Irvine, CA 92697 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Katholieke Univ Leuven Hosp, Dept Gynaecol Oncol, Louvain, Belgium
[4] Northwestern Univ, Evanston, IL USA
[5] Evanston NW Healthcare, Evanston, IL USA
关键词
D O I
10.1016/S0020-7292(06)60040-4
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Quality of life (QOL) is a fundamental consideration for patients with life threatening diseases. Major evolving paradigms are discussed: improved QOL with laparoscopic surgery, the impact on QOL of intraperitoneal chemotherapy for optimally cytoreduced ovarian cancer, combination therapy, sexuality, and survivorship. The goals of treatment for many patients with gynecologic tumors remain largely palliative, and patient reported QOL is the primary outcome determining the utility of treatment. Particularly in this area, QOL endpoints are increasingly important in clinical trials. The QOL issues facing gynecologic cancer patients, the use of validated QOL instruments, recent advances in the evaluation of interventions, and changes in concepts related to QOL are reviewed. (c) 2006 International Federation of Gynecology and Obstetrics. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:S247 / S257
页数:11
相关论文
共 91 条
[21]   Changing patient perceptions of the side effects of cancer chemotherapy [J].
Carelle, N ;
Piotto, E ;
Bellanger, A ;
Germanaud, J ;
Thuillier, A ;
Khayat, D .
CANCER, 2002, 95 (01) :155-163
[22]   What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN) [J].
Cella, D ;
Paul, D ;
Yount, S ;
Winn, R ;
Chang, CH ;
Banik, D ;
Weeks, J .
CANCER INVESTIGATION, 2003, 21 (04) :526-535
[23]   What do global quality-of-life questions really measure? Insights from Hobday et al and the "Do something" rule [J].
Cella, D .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) :3178-3179
[24]   THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE [J].
CELLA, DF ;
TULSKY, DS ;
GRAY, G ;
SARAFIAN, B ;
LINN, E ;
BONOMI, A ;
SILBERMAN, M ;
YELLEN, SB ;
WINICOUR, P ;
BRANNON, J ;
ECKBERG, K ;
LLOYD, S ;
PURL, S ;
BLENDOWSKI, C ;
GOODMAN, M ;
BARNICLE, M ;
STEWART, I ;
MCHALE, M ;
BONOMI, P ;
KAPLAN, E ;
TAYLOR, S ;
THOMAS, CR ;
HARRIS, J .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :570-579
[25]   Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial [J].
Crawford, SC ;
Vasey, PA ;
Paul, J ;
Hay, A ;
Davis, JA ;
Kaye, SB .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8802-8811
[26]  
DENTON AS, 2003, COCHRANE DATABASE SY
[27]  
Donnelly JM, 2000, PSYCHO-ONCOL, V9, P44, DOI 10.1002/(SICI)1099-1611(200001/02)9:1<44::AID-PON431>3.3.CO
[28]  
2-M
[29]   Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer [J].
Doyle, C ;
Crump, M ;
Pintilie, M ;
Oza, AM .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1266-1274
[30]  
Duff MS, 2001, NURS CLIN N AM, V36, P603